海洋微生物类化合物 (R) - 萨尔索林醇对Trypanosoma cruzi有效
Andre G G Tempone1, Mariana B Abiuzi2, Beatriz A de Andrade3
1Instituto Butantan, Pathophysiology, Avenida Vital Brasil 1500, Laboratorio de Fisiopatologia, Instituto Butantan, 05503900, Sao Paulo, BRAZIL.
Chemistry & biodiversity
|February 27, 2025
概括
研究人员发现了R-salsolinol,一种来自Bacillus altitudinis细菌的化物,作为查加斯病的潜在新疗法. 这种化合物显示出显著的抗寄生虫活性和低毒性,为改善药物设计提供了希望.
科学领域:
- 自然产品 化学 化学
- 寄生虫学的寄生虫学
- 药物发现 药物发现 药物发现
背景情况:
- 查加斯病影响全球数百万人,目前的治疗方法有限且有毒.
- 微生物代谢产物是抗感染化合物的丰富来源.
- 对于针对查加斯病的新型治疗药物有着迫切的需求.
研究的目的:
- 从微生物来源识别和描述新的抗查加斯病化合物.
- 评估隔离化合物对Trypanosoma cruzi的疗效和安全性.
- 探索已识别的化合物的药物相似性和潜在的治疗应用.
主要方法:
- 来自Bacillus altitudinis的细菌提取物的生物活性引导分化.
- 使用1H NMR和HR-ESIMS的活性化合物的化学表征.
- 在体外评估抗松体活性对抗型结核菌和细胞内结核菌.
- 在人类单细胞THP-1细胞中进行细胞毒性评估.
- 药物动力学特性和目标相互作用的in silico预测.
主要成果:
- 一种类化合物, (R) - 萨尔索林醇,从Bacillus altitudinis中分离和鉴定出来.
- (R) - 萨尔索林醇显示出显著的三酸性活性 (EC50 = 14 μg/mL) 和对细胞内巨菌的选择性活性 (EC50 = 19 μg/mL).
- 该化合物没有表现出哺乳动物细胞毒性 (CC50>36μg/mL),并且具有良好的in silico类似药物特性,包括高细胞透性和胃肠道吸收.
- 克鲁西派因被确定为 (R) - 盐醇的潜在分子标.
结论:
- 细菌代谢物 (R) - 萨尔索林醇显示出有前途的抗类体活性和有利的安全性.
- 该化合物具有类似药物的特性,适合作为查加斯病治疗药物进一步开发.
- (R) - 萨尔索林醇作为设计新的抗查加斯病药物的宝贵原型.
更多相关视频
06:13Introducing a Gene Knockout Directly Into the Amastigote Stage of Trypanosoma cruzi Using the CRISPR/Cas9 System
Published on: July 31, 2019
8.9K
08:48In Vitro Drug Screening Against All Life Cycle Stages of Trypanosoma cruzi Using Parasites Expressing β-galactosidase
Published on: November 5, 2021
3.2K
相关概念视频
01:22American Trypanosomiasis
Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...